Compare FPI & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FPI | ETON |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 435.7M | 411.9M |
| IPO Year | 2014 | 2018 |
| Metric | FPI | ETON |
|---|---|---|
| Price | $11.47 | $14.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $29.67 |
| AVG Volume (30 Days) | ★ 475.3K | 211.7K |
| Earning Date | 02-26-2026 | 03-17-2026 |
| Dividend Yield | ★ 2.09% | N/A |
| EPS Growth | ★ 296.76 | N/A |
| EPS | ★ 1.27 | N/A |
| Revenue | $52,990,000.00 | ★ $70,316,000.00 |
| Revenue This Year | N/A | $107.23 |
| Revenue Next Year | N/A | $29.72 |
| P/E Ratio | $8.99 | ★ N/A |
| Revenue Growth | N/A | ★ 102.77 |
| 52 Week Low | $9.37 | $11.09 |
| 52 Week High | $12.87 | $23.00 |
| Indicator | FPI | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 70.31 | 34.43 |
| Support Level | $11.08 | $14.62 |
| Resistance Level | $11.60 | $15.73 |
| Average True Range (ATR) | 0.25 | 0.55 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 87.55 | 3.08 |
Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, pictachios, citrus, avacados, strawberies, and edible beans. The company generates its revenues through the rent it receives from its tenants.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.